January 9, 2024 by Chip Davis
2024 Health care outlook: Chip Davis, president and CEO HDA
January 22, 2024, Opinion, Pharmacy
In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. Health care policy issues will inevitably emerge as a topic of the national debate in the 2024 election season. Access and affordability remain part of the dialogue, and implementation of the Inflation Reduction Act —
January 9, 2023 by Chip Davis
CEO at Healthcare Distribution Alliance., Chip Davis is the president
January 9, 2023, Opinion
As we welcome 2023 and the beginning of the 118th Congress, HDA pharmaceutical distributor members’ role as a convener within the health care ecosystem will be more important than ever. Our industry’s value proposition is clear: HDA distributors manage approximately 94% of the market for pharmaceuticals, delivering more than 11 million medicines, vaccines and health
April 22, 2022 by Chip Davis
Chip Davis is the president and CEO of the Healthcare Distribution Alliance, HDA
Leading Headlines, Pharmacy
ARLINGTON, Va. — HDA recognizes the role health care distributors can play in minimizing the healthcare sector’s carbon footprint. Many members are already committing to sustainability initiatives — from adopting eco-friendly packaging to setting carbon neutrality goals. The efforts of HDA and its membership to enhance the healthcare distribution sector’s sustainability is reflected in HDA’s president
December 30, 2021 by Chip Davis
Chip Davis is the president and CEO of the Healthcare Distribution Alliance
Featured Articles, January 10, 2022, Leading Headlines, Opinion, Pharmacy
From the White House to the kitchen table, supply chain disruptions have been on the minds of many Americans. But while the COVID-19 pandemic revealed the limits of operating within a global marketplace, the pharmaceutical supply chain was largely immune to bottlenecks. Consumer goods shortages have challenged us recently, yet pharmacies, health systems and physicians’
April 5, 2021 by Chip Davis
Chip Davis, HDA
Leading Headlines, Pharmacy
For the past year, I have watched the men and women of the healthcare distribution industry go above and beyond on a daily basis to make sure medicines, vaccines, PPE and other medical supplies reached patients and providers across the country. Their energy, determination and commitment have ensured a resilient supply chain during the most
January 4, 2021 by Chip Davis
Chip Davis is the president and chief executive officer at the Healthcare Distribution Alliance.
January 4, 2021, Pharmacy
Our nation is at a defining moment, as we transition to a new administration and Congress and continue to respond to the COVID-19 pandemic. From a health care delivery perspective, the logistics expertise of our industry has never been more relied upon, and scrutinized, than it is today. As the calendar turns to 2021, eradicating
April 17, 2020 by Chip Davis
Chip Davis, COVID-19, HDA
Opinion
Across the country, brave, frontline health care professionals are working around the clock as our nation grapples with the COVID-19 pandemic. These workers — the true heroes of the pandemic — are treating patients, maintaining vital health care operations and serving as emergency responders. In this time of crisis, it is also important to remember
January 10, 2020 by Chip Davis
Association for Accessible Medicines, Chip Davis
January 6, 2020, Opinion
The public continues to name health care costs — and prescription drugs in particular — as a top priority. A recent survey from the Kaiser Family Foundation found that eight in 10 Americans say the cost of prescription drugs is unreasonable. At the same time, the value of generic medicines is well established. Consider this:
January 22, 2019 by Chip Davis
Association for Accessible Medicines, Chip Davis
Featured Articles, January 7, 2019, Leading Headlines, Pharmacy
Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. This past June, Secretary of Health and Human Services Alex Azar told the Senate Finance Committee, “We need a strong, robust generic market.” He followed this statement with an observation that resonated for many of the member companies of the